-
-
-
-
-
-
-
Aeterna Zentaris (AEZS) Announces 2.53M Share and Warrant Offering
-
-
-
-
-
-
-
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS,
-
-
-
-
-
-
-
Aeterna Zentaris Reports Third Quarter 2017 Financial and Operating Results
-
-
-
-
-
-
-
Aeterna Zentaris (AEZS) Hires Financial Advisor to Review Alternatives
-
-
-
-
-
-
-
NDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date
-
-
-
-
-
-
-
Pre-Open Movers 05/01: (OCN) (XXII) (TWTR) Higher; (FNBC) (AEZS) (ITCI) Lower (more...)
-
-
-
-
-
-
-
Aeterna Zentaris Announces At the Market Issuance Program
-
922,445 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All